Lowenstein Sandler advised Sonnet BioTherapeutics, while Sullivan & Worcester advised Chardan Capital Markets on the offering. Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN), a clinical-stage company developing...
Lowenstein Sandler advised Sonnet BioTherapeutics, while Sullivan & Worcester advised Chardan Capital Markets on the offering. Sonnet BioTherapeutics Holdings, Inc. (Nasdaq: SONN), a clinical-stage company developing...